

other cavity, and a second expanded cross-sectional shape having a second cross-sectional area which second cross-sectional shape is variable, said body member having substantially the same longitudinal length when said body member is in its first cross-sectional shape and in its said second cross-sectional shape; said body member at least partially coated with a biological agent, said biological agent inhibiting or reducing a biological condition selected from the group consisting of restenosis, vascular narrowing, in-stent restenosis and combinations thereof, at least a portion of said biological agent releasably coated on said body member.

36. The expandable intraluminal graft of claim 35, wherein said body member include a plurality of end regions, at least two of said end regions having a substantially smooth surface.

37. The expandable intraluminal graft of claim 35, including at least one connector and at least two body members, said at least one of said connectors being connected between at least of said body members, said connector allowing transverse bending flexibility invariant to the plane of bending of said graft.

38. The expandable intraluminal graft of claim 36, including at least one connector and at least two body members, said at least one of said connectors being connected between at least of said body members, said connector allowing transverse bending flexibility invariant to the plane of bending of said graft.

39. The expandable intraluminal graft of claim 35, wherein said body member is at least visible under fluoroscopy.

40. The expandable intraluminal graft of claim 38, wherein said body member is at least visible under fluoroscopy.

41. The expandable intraluminal graft of claim 35, wherein said body member is at least partially treated with Gamma or Beta radiation to reduce the vascular narrowing of the stented section.

42. The expandable intraluminal graft of claim 40, wherein said body member is at least partially treated with Gamma or Beta radiation to reduce the vascular narrowing of the stented section.

43. The expandable intraluminal graft as defined in claim 35, wherein said biological agent includes a PDGF inhibitor.

44. The expandable intraluminal graft as defined in claim 36, wherein said biological agent includes a PDGF inhibitor.

45. The expandable intraluminal graft as defined in claim 39, wherein said biological agent includes a PDGF inhibitor.

46. The expandable intraluminal graft as defined in claim 41, wherein said biological agent includes a PDGF inhibitor.

47. The expandable intraluminal graft as defined in claim 42, wherein said biological agent includes a PDGF inhibitor.

48. The expandable intraluminal graft as defined in claim 43, wherein said PDGF inhibitor includes Trepidil.

49. The expandable intraluminal graft as defined in claim 44, wherein said PDGF inhibitor includes Trepidil.

50. The expandable intraluminal graft as defined in claim 45, wherein said PDGF inhibitor includes Trepidil.

51. The expandable intraluminal graft as defined in claim 46, wherein said PDGF inhibitor includes Trepidil.

52. The expandable intraluminal graft as defined in claim 47, wherein said PDGF inhibitor includes Trepidil.

53. The expandable intraluminal graft of claim 35, including a mounting substance at least partially coated on said body member, said mounting substance at least partially securing said biological agent to said body member.

54. The expandable intraluminal graft of claim 36, including a mounting substance at least partially coated on said body member, said mounting substance at least partially securing said biological agent to said body member.

55. The expandable intraluminal graft of claim 39, including a mounting substance at least partially coated on said body member, said mounting substance at least partially securing said biological agent to said body member.

56. The expandable intraluminal graft of claim 41, including a mounting substance at least partially coated on said body member, said mounting substance at least partially securing said biological agent to said body member.

57. The expandable intraluminal graft of claim 43, including a mounting substance at least partially coated on said body member, said mounting substance at least partially securing said biological agent to said body member.

58. The expandable intraluminal graft of claim 48, including a mounting substance at least partially coated on said body member, said mounting substance at least partially securing said

biological agent to said body member.

59. The expandable intraluminal graft of claim 49, including a mounting substance at least partially coated on said body member, said mounting substance at least partially securing said biological agent to said body member.

60. The expandable intraluminal graft of claim 50, including a mounting substance at least partially coated on said body member, said mounting substance at least partially securing said biological agent to said body member.

61. The expandable intraluminal graft of claim 51, including a mounting substance at least partially coated on said body member, said mounting substance at least partially securing said biological agent to said body member.

62. The expandable intraluminal graft of claim 52, including a mounting substance at least partially coated on said body member, said mounting substance at least partially securing said biological agent to said body member.

63. The expandable intraluminal graft as defined in claim 53, wherein said mounting substance at least partially delays delivery of said biological agent into said body cavity.

64. The expandable intraluminal graft as defined in claim 54, wherein said mounting substance at least partially delays delivery of said biological agent into said body cavity.

65. The expandable intraluminal graft as defined in claim 55, wherein said mounting substance at least partially delays delivery of said biological agent into said body cavity.

66. The expandable intraluminal graft as defined in claim 56, wherein said mounting substance at least partially delays delivery of said biological agent into said body cavity.

67. The expandable intraluminal graft as defined in claim 57, wherein said mounting substance at least partially delays delivery of said biological agent into said body cavity.

68. The expandable intraluminal graft as defined in claim 58, wherein said mounting substance at least partially delays delivery of said biological agent into said body cavity.

69. The expandable intraluminal graft as defined in claim 59, wherein said mounting substance at least partially delays delivery of said biological agent into said body cavity.

70. The expandable intraluminal graft as defined in claim 60, wherein said mounting substance at least partially delays delivery of said biological agent into said body cavity.

71. The expandable intraluminal graft as defined in claim 61, wherein said mounting substance at least partially delays delivery of said biological agent into said body cavity.

72. The expandable intraluminal graft as defined in claim 62, wherein said mounting substance at least partially delays delivery of said biological agent into said body cavity.

---